Abstracts tagged "certolizumab pegol and spondylarthropathy"

Abstract Number: 1372 • 2012 ACR/ARHP Annual Meeting
Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Désirée van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum Berlin, Berlin, Germany, ⁴UCB Pharma, Braine, Belgium, ⁵UCSD School of Medicine, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients' (pts) work productivity.1 The impact of the…
Abstract Number: 777 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study
Robert B. M. Landewé¹, Martin Rudwaleit², Désirée van der Heijde³, Maxime Dougados⁴, Walter P. Maksymowych⁵, Jürgen Braun⁶, Atul A. Deodhar⁷, Christian Stach⁸, Bengt Hoepken⁸, Geoffroy Coteur⁹, Danuta Kielar⁹, Andreas Fichtner⁸, Terri Arledge¹⁰ and Joachim Sieper¹¹, ¹Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ²Endokrinologikum Berlin, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Oregon Health & Science University, Portland, OR, ⁸UCB Pharma, Monheim am Rheim, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Rtp, NC, ¹¹Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Axial spondyloarthritis (axSpA ) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), as defined by the ASAS criteria.1 RAPID-axSpA (NCT01087762) is the first…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].